The Addition of an Immunosuppressant After Loss of Response to Anti-TNF alpha Monotherapy in Inflammatory Bowel Disease: A 2-Year Study

摘要

Background: The addition of an immunosuppressant (IM) after loss of response to anti-TNF alpha monotherapy is an emerging strategy of therapeutic optimization in patients with inflammatory bowel disease (IBD). However, few clinical data have been reported to date. We aimed to evaluate the efficacy and safety of this selective combination therapy in patients with IBD.